3 results match your criteria: "Zhongshan Hospital of Sun Yat-Sen University (Zhongshan City People's Hospital)[Affiliation]"
Adjuvant Chemoradiation Therapy Versus Chemotherapy Alone for Resected Oligodendroglioma: A Surveillance, Epidemiology and End Results (SEER) Analysis.
World Neurosurg
February 2023
Department of Anesthesiology, Zhongshan Hospital of Sun Yat-Sen University (Zhongshan City People's Hospital), Zhongshan, Guangdong, China. Electronic address:
Objective: The benefit of postoperative adjuvant therapy for survival of oligodendrocyte glioma remains unclear. In this study, we compared the effect of chemoradiation therapy (CRT) and chemotherapy (CT) alone in patients who underwent resection. We aim to identify which adjuvant therapy provides more survival benefits.
View Article and Find Full Text PDFOutcomes from the Use of Perioperative Extracorporeal Membrane Oxygenation in Patients Undergoing Thoracic Surgery: An 8-Year Single-Center Experience.
Med Sci Monit
November 2021
Department of Cardiothoracic Surgery, Zhongshan Hospital of Sun Yat-Sen University (Zhongshan People's Hospital), Zhongshan, Guangdong, China (mainland).
Article Synopsis
- ECMO is crucial in thoracic surgery, with a study analyzing outcomes of 22 patients over 8 years, showing benefits in cardiac and respiratory support.
- Most patients (90.9%) were successfully decannulated, and 77.2% survived to discharge, though complications were reported, including hemorrhage and sepsis.
- The study found no significant survival differences based on ECMO type (veno-venous or veno-arterial) or timing (pre- or post-surgery), emphasizing the need for surgeons to effectively manage ECMO indications and complications for optimal results.
High-resolution mass spectrometry-based approach for the identification and profiling of the metabolites of taletrectinib formed in liver microsomes.
Drug Test Anal
June 2021
Department of Hematology, Zhongshan Hospital of Sun Yat-Sen University & Zhongshan City People's Hospital, Zhongshan, China.
Taletrectinib is a potent, orally active, and selective ROS1/NTRK kinase inhibitor. The aim of this study was to study the metabolism of taletrectinib in rat, dog, and human liver microsomes. The biotransformation of taletrectinib was carried out using rat, dog, and human liver microsomes supplemented with nicotinamide adenine dinucleotide phosphate tetrasodium salt (NADPH) and uridine diphosphate glucuronic acid (UDPGA).
View Article and Find Full Text PDF